• News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Digital edition
    • Archived issues
    • Media kit
    • Submit Press Release
  • White Papers
  • Events
  • Suppliers
  • E-Alert
  • Contact us
  • Subscribe newsletter
  • Search
  • Menu Menu
International Hospital
  • AI
  • Cardiology
  • Oncology
  • Neurology
  • Genetics
  • Orthopaedics
  • Research
  • Surgery
  • Innovation
  • Medical Imaging
  • MedTech
  • Obs-Gyn
  • Paediatrics

Archive for category: Corona News

Corona News

ndd’s new inline filters offer additional protection against COVID-19 during lung function tests

, 26 August 2020/in Corona News, Product News /by 3wmedia

ndd Medical Technologies (ndd), a leading provider of diagnostic technology enabling healthcare professionals in the early detection of COPD and other chronic lung diseases, has introduced new single patient-use, inline filters for its lung function testing devices, in response to the global COVID-19 pandemic. Ensuring an added level of safety, the new filters can be used with ndd’s portable EasyOne spirometry range, including the EasyOne Air, EasyOne Pro, and EasyOne Pro LAB. EasyOne spirometers are popular among pulmonologists and medical researchers as they provide sensitive, reliable, real-time lung function results and diagnosis of chronic lung diseases, even at the point of care.
The EasyOne product line was originally designed with a strong focus on infection control with easy-to-wipe surfaces, single-use parts for anything that comes into contact with a patient’s breath, and ndd’s unique spirette and flow tube design which protects the flow sensor from cross-contamination. Now, when performing spirometry and testing of the diffusing capacity of the lungs for carbon monoxide (DLCO tests), the new EasyOne inline, single patient-use filters provide “double protection” for technicians and patients by keeping the ambient environment clean, without significantly affecting the EasyOne’s sensitivity.
ndd’s rigorous sensitivity tests have shown that the new inline filters do not significantly affect the device’s sensitivity and show comparable results in 24 waveform testing, (as required by ATS/ERS) and pass testing requirements. World-renowned medical research organizations – such as Johns Hopkins University, University Hospital Zurich and University of Cape Town – are partnering with ndd to assess the long-term lung damage caused by SARS-CoV-2.
Dr Trishul Siddharthan, Assistant Professor of Pulmonary and Critical Care Medicine at Johns Hopkins University, commented: “There is a lot of research underway to investigate the long-term effects of COVID-19. Our research group has been partnering with ndd thanks to the reliability of these spirometers in global settings and the ease of cleaning these devices during the pandemic to ensure safety.”
Prof. Friedrich Thienemann, General Medicine & Global Health research group, University of Cape Town and University Hospital Zurich, also noted: “In order to measure lung functions in resource-constrained settings like South African townships, one needs a device that is portable, point-of-care, easy-to-use, low-maintenance, and reliable without complicated calibration. EasyOne Pro LAB is that device.”
Incorporating ndd’s patented TrueFlow ultrasound technology, the EasyOne translates airflow into ultrasound signals which are measured by the sensors, so the patient’s breath does not come into contact with the sensors. This helps to prevent contamination and minimizes the cleaning required for safe use, while enabling a lifetime of calibration-free accuracy for flow and volume measurements.
To learn more about ndd, visit: www.nddmed.com
Read more

https://interhospi.com/wp-content/uploads/sites/3/2020/08/IH_PN_ndd.jpg 720 720 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:31:322021-01-08 12:10:16ndd’s new inline filters offer additional protection against COVID-19 during lung function tests

Xenios sees growing demand for ECMO devices

, 26 August 2020/in Corona News, Product News /by 3wmedia

Xenios AG, a company of the Fresenius Medical Care Group, reports that it has seen a significant growth in demand for its extracorporeal membrane oxygenation (ECMO) devices, which can be used for the treatment of patients who develop severe pneumonia and acute respiratory distress syndrome (ARDS) due to COVID-19 infection.
Jürgen Böhm, CMO of Xenios, explained that for critically ill COVID-19 patients with acute lung failure and refractory hypoxemia – despite use of standard therapy – “our treatment often remains the last therapeutic option and has been a lifesaver for many patients”.
Xenios’s ECMO therapy bypasses the function of the lungs. The patient’s blood is freed from carbon dioxide outside the body and enriched with oxygen. The lungs are thus given time to heal. Because of the increase of critically ill COVID-19 patients, more physicians are opting for ECMO therapy, and thus the increase in demand for Xenios’s ECMO devices.
To meet the demand, the company has increased production of its ECMO devices. “We have put many measures in place to maximize the utilization of our capacity to manufacture ECMO devices as well as patient kits. Our biggest challenge right now is the availability of specific components for our products,” said Andreas Terpin, CEO of Xenios.
For more information, visit: www.xenios-ag.com
Read more

https://interhospi.com/wp-content/uploads/sites/3/2020/08/PRODUCT_XENIOS.jpg 749 1000 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:31:322021-01-08 12:10:17Xenios sees growing demand for ECMO devices

THE COVID-19 THREAT

, 26 August 2020/in Corona News, Editors' Picks, Featured Articles /by 3wmedia

As the threat of a COVID-19 pandemic stares us in the face, it may be opportune to consider some scenarios ahead, especially in light of lessons from other, similar outbreaks in recent decades.
The first problem is sporadic bursts of public concern, alternating with periods of denial. Managing both requires measured doses of reliable information from authoritative sources. Such measurement is a delicate art at the best of times. During a crisis, media hype can mutate it easily into mass misinformation.
Similarly, the threat of terrorism has close parallels with each of the above aspects.

https://interhospi.com/wp-content/uploads/sites/3/2020/08/PAN0028-IH-article-Coronavirus-v2-1.jpg 1361 1000 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:16:482021-01-08 12:29:43THE COVID-19 THREAT
Page 6 of 6«‹456

Latest issue of International Hospital

April 2024

9 July 2025

New stem cell bank enables global Alzheimer’s research

9 July 2025

DNA-guided prescribing shows major clinical impact in NHS trial

8 July 2025

Siemens Healthineers partners with Charité for preventive medicine research

Digital edition
All articles Archived issues

Free subscription

View more product news

Get our e-alert

The medical devices information portal connecting healthcare professionals to global vendors

Sign in for our newsletter
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Archived issues
    • Media kit
    • Submit Press Release

Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@interhospi.com

PanGlobal Media IS not responsible for any error or omission that might occur in the electronic display of product or company data.

Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlyCookie settings

Cookie and Privacy Settings



How we use cookies

We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.

Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.

We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.

We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.

.

Google Analytics Cookies

These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.

If you do not want us to track your visit to our site, you can disable this in your browser here:

.

Other external services

We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page

Google Webfont Settings:

Google Maps Settings:

Google reCaptcha settings:

Vimeo and Youtube videos embedding:

.

Privacy Beleid

U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.

Privacy policy
Accept settingsHide notification only

Sign in for our newsletter

Free subscription